ArticleFrontiers in immunology2025
Immunomodulatory and anti-inflammatory effects of agave fructans in atopic dermatitis: gut microbiota and short-chain fatty acid implication.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioactive Potential ofPharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disorder resulting from the interplay of genetic and environmental factors, with a dysregulated type-2 immune response. The association between AD onset and intestinal dysbiosis supports research into nutritional interventions such as fermentable fibers intake. Agave-derived fructans (AFs) display prebiotic activity, modulating gut microbial communities that may positively influence immune functions. In this study, we evaluated the anti-inflammatory and immunomodulatory effects of oral AFs in a rat AD model. Methods: AD-like lesions were induced in the ear of Wistar rats by frequent application of 2,4-dinitrochlorobenzene (DNCB). AFs (0.1, 1, 5 g/kg) from Results: Treatment with AFs at 0.1 g/kg significantly reduced ear thickness at 1- and 6-hours post-DNCB application. Similarly, ear edema at 1 hour was attenuated, and inhibition of the NF-κB inflammatory pathway was detected. After AFs treatment at 0.1 g/kg, serum IgE levels were normalized to those of control animals. All AFs significantly decreased dermal mast cell and eosinophil counts, as well as epidermal thickening, with greater efficacy observed at lower doses. The scratching behavior remained unchanged across groups. AFs reduced Conclusion: AFs exhibit anti-inflammatory, immunoregulatory, and microbiota-modulatory properties in both the gut and skin compartments, in a non-linear dose-response manner. These findings suggest that the intake of AFs may contribute to the therapeutic management of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.